PALM BEACH, Florida, July 8, 2020 /PRNewswire/ -- The global brain tumor drugs market was valued at about $2.4 billion in 2018 and is expected to grow to $3.41 billion at a CAGR of 9.2% through 2022. The brain tumor drugs market consist of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and locations of the tumor. North America was the largest region in the brain tumor drugs market in 2018. This region is expected to remain the largest during the next five years. The brain tumor drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023. A recent article from The Business Research Company said: "The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections and sedentary lifestyle. In 2015, these disorders were ranked as the leading cause group of Disability Adjusted Life Years (DALYs), which is the number of years lost due to ill-health, disability or early death. For example, as per the North American Brain Tumor Society, around 700,000 people in the region were suffering from Brain Tumors in 2015, which increased by around 78,000 people in 2016. The increasing number of patients with neurological disorders including brain tumor, is leading to a rise in the demand for the drugs used in their treatment." Active biotech and pharma companies in the markets this week include CNS Pharmaceuticals, Inc. /zigman2/quotes/214919321/composite CNSP -3.01% , VBI Vaccines Inc. /zigman2/quotes/201705917/composite VBIV -3.19% , PDS Biotechnology Corporation /zigman2/quotes/206693095/composite PDSB -5.10% , Cardiff Oncology, Inc. /zigman2/quotes/201555650/composite CRDF +1.40% , Clovis Oncology, Inc. /zigman2/quotes/201295534/composite CLVS -1.43% .
The article continued : "Companies in the brain tumor market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in dosage of the drugs, improved shelf life and reduce toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity.
CNS Pharmaceuticals, Inc. /zigman2/quotes/214919321/composite CNSP -3.01% BREAKING NEWS: CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers - CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced today it has completed shipping its Active Pharma Ingredient (API) to both Maryland based Pharmaceutics International, Inc., (Pii) and Italian BSP Pharmaceuticals S.p.A., (BSP), respectively, for the production of Berubicin.
"As we continue to prepare for our upcoming Berubicin Phase 2 trial, ensuring proper manufacturing and delivery of drug product is a key priority," stated John Climaco, CEO of CNS Pharmaceuticals. "We are excited to execute on yet another key milestone, and deliver Berubicin's API to our trusted partners PII and BSP. We will continue our focus on executing upon all of the necessary steps as we look to pave the way for our upcoming U.S. Phase 2 trial, expected to initiate during the fourth quarter of this year."
CNS previously entered into manufacturing contracts with Pii and BSP for the production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors. The decision to implement a binary manufacturing strategy mitigates COVID-19 related manufacturing risks for the upcoming Phase I study in Poland and the upcoming U.S. Phase 2 trial. The first API shipments to PII and BSP commenced in June. Read this full release and more news for CNSP at: https://www.financialnewsmedia.com/news-cnsp/
Other recent developments in the biotech industry include:
VBI Vaccines Inc. /zigman2/quotes/201705917/composite VBIV -3.19% recently announced that updated Part B data from its ongoing Phase 1/2a study of VBI-1901, the company's cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients is being presented in an e-poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22-24, 2020.
Emerging data from the ongoing Phase 1/2a study suggest that patients with a normal baseline CD4+/CD8+ T cell ratio may be more likely to experience delayed progression or tumor reduction, reflected as a tumor response. Five out of the six tumor responses seen to-date, including a recently confirmed partial response (PR), defined as a tumor reduction of more than 50% per the Response Assessment in Neuro-Oncology (RANO) criteria, suggest that the biomarker may predict patients most likely to respond to, and derive clinical benefit from, treatment with VBI-1901. Based on the data seen to-date, VBI is exploring a randomized, controlled, registrational clinical study for the next phase of development, which, subject to approval from regulatory bodies, could begin in 2021. In parallel, enrollment in the Phase 1/2a Part B study arm of VBI-1901 in combination with GSK's AS01B adjuvant systems continues, with immunologic and tumor data expected in Q4 2020.
PDS Biotechnology Corporation /zigman2/quotes/206693095/composite PDSB -5.10% recently announced the publication of data generated by the National Cancer Institute (NCI) based on preclinical studies of PDS Biotech's lead clinical program, PDS0101, in combination with two other investigational anti-cancer agents.
The article "Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine" by Rumfield et al. was published in the Journal for ImmunoTherapy of Cancer, and provides strong rationale for clinical evaluation of this three-component treatment combination in a recently initiated NCI-led Phase 2 clinical trial.
The results of the NCI's preclinical study indicated that PDS0101 generated both human papillomavirus (HPV)-specific T-cells and an associated antitumor response when used as a monotherapy. When PDS0101 was combined with two other development-stage anti-cancer agents, Bintrafusp alfa (M7824) and NHS-IL12, the data suggest the agents worked synergistically to provide enhanced tumor regression and T-cell response as compared to the agents alone.
Cardiff Oncology, Inc. /zigman2/quotes/201555650/composite CRDF +1.40% a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, recently announced presentation of final results of its Phase 1b study, and preliminary positive data from its Phase 2 study, in relapsed or refractory acute myeloid leukemia (AML). The data was presented as a virtual poster presentation at the European Hematology Association (EHA) annual conference.
The presentation highlighted the efficacy, durability of response, favorable safety and tolerability profile, as well as correlative biomarker data. Anti-leukemic activity was observed at a wide range of onvansertib doses (27 to 90 mg/m  ), indicating a large therapeutic window.
Clovis Oncology, Inc. /zigman2/quotes/201295534/composite CLVS -1.43% recently announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis' Rubraca ® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb's /zigman2/quotes/202559280/composite BMY -0.13% PD-1 inhibitor, OPDIVO [®] (nivolumab), as front-line maintenance treatment of newly-diagnosed advanced ovarian cancer. ATHENA is the first front-line switch maintenance study designed to show PARP monotherapy and PARP/PD-1 combination therapy in one study design.
"The completion of target patient enrollment in the Phase 3 ATHENA trial is an important milestone for Clovis and a critical step toward developing additional therapeutic options for women with advanced ovarian cancer," said Patrick J. Mahaffy, President and Chief Executive Officer of Clovis Oncology. "This was a tremendous effort by trial investigators, our collaborators and our dedicated Clovis team to complete target enrollment in this 1,000-patient study in under two years. Most important, we are grateful to all of the patients who participated in this study."
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by CNS Pharmaceuticals, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: firstname.lastname@example.org - +1 (561)325-8757
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
Copyright (C) 2020 PR Newswire. All rights reserved